Michal Gilon Ohev Zion
Direttore Tecnico/Scientifico/R&S presso BioCancell Therapeutics, Inc.
Profilo
Michal Gilon Ohev Zion is currently the Vice President-Research & Development at BioCancell Therapeutics, Inc. She previously worked as the Vice President-Research & Development at Anchiano Therapeutics Ltd.
Dr. Gilon Ohev Zion received her undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Posizioni attive di Michal Gilon Ohev Zion
| Società | Posizione | Inizio |
|---|---|---|
BioCancell Therapeutics, Inc.
 BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Direttore Tecnico/Scientifico/R&S | 01/02/2013 |
Precedenti posizioni note di Michal Gilon Ohev Zion
| Società | Posizione | Fine |
|---|---|---|
| ANCHIANO THERAPEUTICS LTD. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Michal Gilon Ohev Zion
| The Hebrew University of Jerusalem | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Health Technology |
Anchiano Therapeutics Ltd.
 Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel. | Health Technology |
- Borsa valori
- Insiders
- Michal Gilon Ohev Zion
